Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Exploratory study of NS 065/NCNP 01 in Duchenne muscular dystrophy

Next Previous
Trial Profile

Exploratory study of NS 065/NCNP 01 in Duchenne muscular dystrophy

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Viltolarsen (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Adverse reactions; First in man; Registrational
  • Sponsors Nippon Shinyaku

Most Recent Events

  • 13 Aug 2020 According to an Nippon Shinyaku media release, the U.S. Food & Drug Administration (FDA) has approved VILTEPSO (viltolarsen) injection for patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping therapy. DMD is a progressive muscle disease that primarily occurs in boys due to a genetic mutation in the dystrophin gene.
  • 19 Apr 2018 According to a Nippon Shinyaku media release, registry of Muscular Dystrophy (Remudy) was utilized for patient recruitment in The Study.
  • 19 Apr 2018 Results published in the Nippon Shinyaku Media Release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top